| CEUAX | STITX | CEUAX / STITX | |
| Total Expense Ratio | 0.85 | 1.05 | 81% |
| Annual Report Gross Expense Ratio | 0.85 | 1.23 | 69% |
| Fund Existence | 24 years | 31 years | - |
| Gain YTD | 21.268 | 7.255 | 293% |
| Front Load | 4% | N/A | - |
| Min. Initial Investment | 250 | 100000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 133B | 304M | 43,750% |
| Annual Yield % from dividends | 0.63 | 0.00 | - |
| Returns for 1 year | 14.42 | -19.62 | -74% |
| Returns for 3 years | 33.89 | -10.48 | -324% |
| Returns for 5 years | 4.47 | -28.25 | -16% |
| Returns for 10 years | 51.84 | -19.18 | -270% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RGBLX | 41.95 | 0.28 | +0.67% |
| American Funds Global Balanced R1 | |||
| SMDLX | 23.28 | N/A | N/A |
| ClearBridge Tactical Dividend Income C | |||
| FTDZX | 194.72 | N/A | N/A |
| Franklin Biotechnology Discovery Adv | |||
| MGGIX | 38.15 | N/A | N/A |
| Morgan Stanley Inst Global Opp I | |||
| ETNEX | 14.16 | N/A | N/A |
| Eventide Exponential Technologies N | |||